Essential1 Study

Research Studies

Praxis Precision Medicines is excited to announce that the Essential1 Phase 2b topline data is now available. Results show potential for ulixacaltamide (previously known as PRAX-944) to transform the treatment of essential tremor. To learn more visit We would like to thank everyone involved in helping us complete our enrollment in this clinical study, including the patients, care partners and advocacy collaborators, including IETF.